Business Description
![Catalyst Pharmaceuticals Inc Catalyst Pharmaceuticals Inc logo](https://static.gurufocus.com/logos/0C00000L1Q.png?14)
Catalyst Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US14888U1016
Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 89.51 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 14.98 | |||||
Beneish M-Score | -2.75 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 46.2 | |||||
3-Year EBITDA Growth Rate | 39.2 | |||||
3-Year EPS without NRI Growth Rate | -6.1 | |||||
3-Year FCF Growth Rate | 8.7 | |||||
3-Year Book Growth Rate | 30.4 | |||||
Future 3-5Y Total Revenue Growth Rate | 16.58 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 36.73 | |||||
9-Day RSI | 43.08 | |||||
14-Day RSI | 46.31 | |||||
6-1 Month Momentum % | 6.98 | |||||
12-1 Month Momentum % | 20.04 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.09 | |||||
Quick Ratio | 4.83 | |||||
Cash Ratio | 3.9 | |||||
Days Inventory | 87.95 | |||||
Days Sales Outstanding | 42.28 | |||||
Days Payable | 50.15 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 | |||||
Shareholder Yield % | -7.61 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.74 | |||||
Operating Margin % | 19.04 | |||||
Net Margin % | 15.83 | |||||
FCF Margin % | 19.57 | |||||
ROE % | 16.22 | |||||
ROA % | 13.67 | |||||
ROIC % | 24.67 | |||||
ROC (Joel Greenblatt) % | 615.02 | |||||
ROCE % | 19.03 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 28.93 | |||||
Forward PE Ratio | 9.91 | |||||
PE Ratio without NRI | 28.93 | |||||
Shiller PE Ratio | 93.12 | |||||
Price-to-Owner-Earnings | 75.1 | |||||
PS Ratio | 4.33 | |||||
PB Ratio | 3.28 | |||||
Price-to-Tangible-Book | 4.89 | |||||
Price-to-Free-Cash-Flow | 23.11 | |||||
Price-to-Operating-Cash-Flow | 10.83 | |||||
EV-to-EBIT | 19.64 | |||||
EV-to-Forward-EBIT | 9.31 | |||||
EV-to-EBITDA | 13.49 | |||||
EV-to-Revenue | 3.74 | |||||
EV-to-Forward-Revenue | 3.31 | |||||
EV-to-FCF | 18.85 | |||||
Price-to-Projected-FCF | 2.05 | |||||
Price-to-Graham-Number | 2.51 | |||||
Price-to-Net-Current-Asset-Value | 5.76 | |||||
Price-to-Net-Cash | 8.16 | |||||
Earnings Yield (Greenblatt) % | 5.09 | |||||
FCF Yield % | 4.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Catalyst Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 380.152 | ||
EPS (TTM) (€) | 0.492 | ||
Beta | 0.99 | ||
Volatility % | 36.99 | ||
14-Day RSI | 46.31 | ||
14-Day ATR (€) | 0.305013 | ||
20-Day SMA (€) | 14.775 | ||
12-1 Month Momentum % | 20.04 | ||
52-Week Range (€) | 10.655 - 15.635 | ||
Shares Outstanding (Mil) | 118.12 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Catalyst Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Catalyst Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Catalyst Pharmaceuticals Inc Frequently Asked Questions
What is Catalyst Pharmaceuticals Inc(FRA:CN2)'s stock price today?
The current price of FRA:CN2 is €14.28. The 52 week high of FRA:CN2 is €15.64 and 52 week low is €10.66.
When is next earnings date of Catalyst Pharmaceuticals Inc(FRA:CN2)?
The next earnings date of Catalyst Pharmaceuticals Inc(FRA:CN2) is 2024-08-09 Est..
Does Catalyst Pharmaceuticals Inc(FRA:CN2) pay dividends? If so, how much?
Catalyst Pharmaceuticals Inc(FRA:CN2) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |